## Daniel D Sjoberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7593897/publications.pdf

Version: 2024-02-01

128 papers 4,111 citations

34 h-index 59 g-index

129 all docs 129 docs citations

times ranked

129

5442 citing authors

#	Article	IF	CITATIONS
1	Estimating patient health in prostate cancer treatment counseling. Prostate Cancer and Prostatic Diseases, 2023, 26, 271-275.	2.0	3
2	Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. BJU International, 2022, 129, 463-469.	1.3	9
3	Association of Family History of Cancer with Clinical and Pathological Outcomes for Prostate Cancer Patients on Active Surveillance. Journal of Urology, 2022, , 101097JU0000000000000668.	0.2	1
4	Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD) Tj ETQq0 0 0 rg	gB <b>T.#</b> Overlo	ak 10 Tf 50
5	Learning curve for robot-assisted laparoscopic radical prostatectomy in a large prospective multicentre study. Scandinavian Journal of Urology, 2022, 56, 182-190.	0.6	O
6	Ureteroâ€enteric stricture outcomes: secondary analysis of a randomised controlled trial comparing open versus robotâ€assisted radical cystectomy. BJU International, 2022, 130, 809-814.	1.3	3
7	Prospective validation of microseminoproteinâ€Î² added to the 4Kscore in predicting highâ€grade prostate cancer in an international multicentre cohort. BJU International, 2021, 128, 218-224.	1.3	3
8	Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial. BJU International, 2021, 127, 361-368.	1.3	24
9	Optimizing MRI-targeted prostate biopsy: the diagnostic benefit of additional targeted biopsy cores. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 193.e1-193.e6.	0.8	9
10	Photoselective Vaporization of the Prostate in the Management of Lower Urinary Tract Symptoms in Prostate Cancer Patients on Active Surveillance. Urology, 2021, 156, 225-230.	0.5	1
11	Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. Journal of Urology, 2021, 205, 400-406.	0.2	6
12	Functional and Oncological Outcomes of Renal Surgery for Hilar Tumors: Informing the Decisions in Risk-Adapted Management. Urology, 2021, , .	0.5	0
13	Clinical utility of subclassifying positive surgical margins at radical prostatectomy. BJU International, 2021, , .	1.3	2
14	Prospective Phase II Study to Evaluate Response to Two Induction Courses (12 intravesical) Tj ETQq0 0 0 rgBT /O	verlock 10 0.5	Tf 50 227 To 4
15	Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. European Urology Oncology, 2021, 4, 532-539.	2.6	75
16	Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 495.e17-495.e24.	0.8	1
17	The Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical Prostatectomy: Clinically Integrated, Cluster, Randomized Trial. Journal of Urology, 2021, 206, 662-668.	0.2	6
18	Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution. Minerva Urology and Nephrology, 2021, 73, 481-488.	1.3	5

#	Article	IF	CITATIONS
19	Associations between intraoperative factors and surgeons' self-assessed operative satisfaction. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 61-68.	1.3	6
20	Predictors of Benign Ureteroenteric Anastomotic Strictures After Radical Cystectomy and Urinary Diversion. Urology, 2020, 144, 225-229.	0.5	22
21	Value of Partial Nephrectomy for Renal Cortical Tumors of cT2 or Greater Stage: A Risk-benefit Analysis of Renal Function Preservation Versus Increased Postoperative Morbidity. European Urology Oncology, 2020, 3, 365-371.	2.6	10
22	Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 204-209.	0.8	8
23	Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. European Urology, 2020, 77, 501-507.	0.9	57
24	Extensive disease among potential candidates for hemiâ€ablative focal therapy for prostate cancer. International Journal of Urology, 2020, 27, 179-185.	0.5	1
25	Genomeâ€wide association study identifies novel single nucleotide polymorphisms having ageâ€specific effect on prostateâ€specific antigen levels. Prostate, 2020, 80, 1405-1412.	1.2	3
26	Asian-American Race and Urinary Continence After Radical Prostatectomy. European Urology Open Science, 2020, 22, 51-53.	0.2	3
27	A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. British Journal of Cancer, 2020, 123, 604-609.	2.9	9
28	Routine Postoperative Hemoglobin Assessment Poorly Predicts Transfusion Requirement among Patients Undergoing Minimally Invasive Radical Prostatectomy. Urology Practice, 2020, 7, 299-304.	0.2	2
29	Primary urethral cancer: treatment patterns and associated outcomes. BJU International, 2020, 126, 359-366.	1.3	7
30	Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. Journal of Urology, 2020, 203, 1122-1127.	0.2	58
31	Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center. Journal of Urology, 2020, 203, 1117-1121.	0.2	28
32	Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years. Journal of Urology, 2020, 204, 281-288.	0.2	19
33	Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations. Journal of Urology, 2020, 204, 460-465.	0.2	2
34	Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. Journal of Urology, 2020, 204, 677-684.	0.2	13
35	Reply by Authors. Journal of Urology, 2020, 203, 1121-1121.	0.2	0
36	Reply by Authors. Journal of Urology, 2020, 204, 287-288.	0.2	0

#	Article	IF	Citations
37	Reply by Authors. Journal of Urology, 2020, 204, 684-684.	0.2	О
38	Phase III Trial of Intravenous Mannitol Versus Placebo During Nephron-sparing Surgery: Post Hoc Analysis of 3-yr Outcomes. European Urology Focus, 2019, 5, 977-979.	1.6	5
39	Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. Prostate, 2019, 79, 1079-1089.	1.2	28
40	Can We Improve the Preoperative Prediction of Prostate Cancer Recurrence With Multiparametric MRI?. Clinical Genitourinary Cancer, 2019, 17, e745-e750.	0.9	7
41	Patient-reported pain, discomfort, and anxiety during magnetic resonance imaging-targeted prostate biopsy. Canadian Urological Association Journal, 2019, 14, E202-E208.	0.3	7
42	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. European Urology, 2019, 75, 399-407.	0.9	43
43	Innovations in Statistical Review at European Urology. European Urology, 2019, 75, 1-2.	0.9	3
44	Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer. Journal of Urology, 2019, 201, 77-83.	0.2	30
45	Clinical Usefulness of Prostate and Tumor Volume Related Parameters following Radical Prostatectomy for Localized Prostate Cancer. Journal of Urology, 2019, 201, 535-540.	0.2	19
46	Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. Urology, 2018, 114, 133-138.	0.5	12
47	Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. European Urology, 2018, 73, 941-948.	0.9	30
48	Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy. BJU International, 2018, 122, 627-632.	1.3	24
49	Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?. Journal of Urology, 2018, 199, 1502-1509.	0.2	4
50	Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. Urology, 2018, 118, 114-118.	0.5	7
51	Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. Clinical Genitourinary Cancer, 2018, 16, e903-e908.	0.9	16
52	Importance of wide reâ€resection in adult spermatic cord sarcomas: Report on oncologic outcomes at a single institution. Journal of Surgical Oncology, 2018, 117, 1464-1468.	0.8	6
53	Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. European Urology, 2018, 73, 890-896.	0.9	87
54	Concordance between patient-reported and physician-reported sexual function after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 80.e1-80.e6.	0.8	3

#	Article	IF	Citations
55	Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients?. European Urology, 2018, 73, 33-37.	0.9	11
56	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e113-e120.	0.9	7
57	Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens. European Urology, 2018, 73, 488-490.	0.9	20
58	Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial. European Urology, 2018, 73, 53-59.	0.9	41
59	Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. Journal of Urology, 2018, 199, 961-968.	0.2	7
60	Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder. Clinical Genitourinary Cancer, 2018, 16, e23-e27.	0.9	19
61	Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device. Urology, 2018, 122, 121-126.	0.5	5
62	Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. European Urology, 2018, 74, 465-471.	0.9	189
63	Effects of pathological upstaging or upgrading on metastasis and cancerâ€specific mortality in men with clinical lowâ€risk prostate cancer. BJU International, 2018, 122, 1003-1009.	1.3	35
64	Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial. European Urology Oncology, 2018, 1, 353-360.	2.6	61
65	Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL, and PADUA Systems. European Urology Oncology, 2018, 1, 428-434.	2.6	15
66	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World Journal of Urology, 2018, 36, 1973-1980.	1.2	10
67	Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. European Urology, 2018, 74, 710-719.	0.9	47
68	The natural history of large renal masses followed on observation. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 362.e17-362.e21.	0.8	14
69	Value of a Statistical Model Based on Four Kallikrein Markers in Blood, Commercially Available as 4Kscore, in All Reasonable Prostate Biopsy Subgroups. European Urology, 2018, 74, 535-536.	0.9	11
70	A Feasibility Study of Restorative Yoga Versus Vigorous Yoga Intervention for Sedentary Breast and Ovarian Cancer Survivors. International Journal of Yoga Therapy, 2018, 28, 79-85.	0.4	5
71	Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically. World Journal of Urology, 2017, 35, 51-56.	1.2	13
72	Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral. Breast Cancer Research and Treatment, 2017, 162, 275-282.	1,1	3

#	Article	IF	Citations
73	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. European Urology, 2017, 72, 448-454.	0.9	61
74	Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 151.e9-151.e15.	0.8	13
75	Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. Journal of Urology, 2017, 197, 1041-1047.	0.2	23
76	The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 35.e1-35.e5.	0.8	21
77	Nephrometry scores and perioperative outcomes following robotic partial nephrectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 1075-1083.	0.7	11
78	The Brier score does not evaluate the clinical utility of diagnostic tests or prediction models. Diagnostic and Prognostic Research, 2017, 1, 19.	0.8	66
79	Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063). Bladder Cancer, 2017, 3, 113-119.	0.2	13
80	Improving Cancer Care Through the Patient Experience: How to Use Patient-Reported Outcomes in Clinical Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 695-704.	1.8	55
81	Impact of stage migration and practice changes on highâ€risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. BJU International, 2016, 117, 740-747.	1.3	28
82	Variation in serum prostate-specific antigen levels in men with prostate cancer managed with active surveillance. BJU International, 2016, 118, 535-540.	1.3	7
83	Comparative Effectiveness of Targeted Prostate Biopsy Using Magnetic Resonance Imaging Ultrasound Fusion Software and Visual Targeting: a Prospective Study. Journal of Urology, 2016, 196, 697-702.	0.2	47
84	A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. Journal of Urology, 2016, 196, 1014-1020.	0.2	41
85	Association between number of prostate biopsies and patientâ€reported functional outcomes after radical prostatectomy: implications for active surveillance protocols. BJU International, 2016, 117, E46-51.	1.3	9
86	Impact of Ureteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes. Urology, 2016, 94, 148-153.	0.5	33
87	Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2705-2711.	0.8	74
88	Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites. Journal of Surgical Oncology, 2016, 114, 375-379.	0.8	39
89	Low yield of surveillance imaging after surgery for T1 kidney cancer. World Journal of Urology, 2016, 34, 949-953.	1.2	4
90	The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 239.e1-239.e8.	0.8	25

#	Article	IF	Citations
91	Erectile Function Recovery after Radical Prostatectomy in Men with High Risk Features. Journal of Urology, 2016, 196, 507-513.	0.2	14
92	The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance. Journal of Urology, 2016, 196, 374-381.	0.2	61
93	Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 259.e1-259.e8.	0.8	56
94	Preoperative Chemoprophylaxis Is Safe in Major Oncology Operations and Effective at Preventing Venous Thromboembolism. Journal of the American College of Surgeons, 2016, 222, 129-137.	0.2	34
95	An Arterial Based Complexity (ABC) Scoring System to Assess the Morbidity Profile of Partial Nephrectomy. European Urology, 2016, 69, 72-79.	0.9	75
96	The Prognostic Impact of a Positive Vascular Margin on pT3 Clear Cell Renal Cell Carcinoma. Journal of Urology, 2016, 195, 264-269.	0.2	15
97	Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically. World Journal of Urology, 2016, 34, 539-544.	1.2	12
98	A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. European Urology, 2016, 69, 505-511.	0.9	77
99	Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes. European Urology, 2016, 69, 143-148.	0.9	54
100	Longâ€term oncological outcomes of a phase <scp>II</scp> trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, highâ€risk prostate cancer. BJU International, 2015, 116, 50-56.	1.3	16
101	Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms. BJU International, 2015, 116, 366-372.	1.3	4
102	A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer. European Urology, 2015, 68, 464-470.	0.9	320
103	Age is Associated with Upgrading at Confirmatory Biopsy among Men with Prostate Cancer Treated with Active Surveillance. Journal of Urology, 2015, 194, 1607-1611.	0.2	18
104	Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience. Journal of Urology, 2015, 193, 1911-1917.	0.2	40
105	Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. European Urology, 2015, 67, 1042-1050.	0.9	453
106	Decision Analysis of Dutasteride Use for Patients With Negative Prostate Biopsy. Urology, 2015, 85, 337-342.	0.5	2
107	Guidelines for Reporting of Statistics in European Urology. European Urology, 2015, 67, 181-187.	0.9	85
108	Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma. Journal of Urology, 2015, 194, 310-315.	0.2	36

#	Article	IF	CITATIONS
109	Comparing surgical infections in National Surgical Quality Improvement Project and an Institutional Database. Journal of Surgical Research, 2015, 196, 416-420.	0.8	15
110	Ambulatory Extended Recovery: Safely Transitioning to Overnight Observation for Minimally Invasive Prostatectomy. Urology Practice, 2015, 2, 121-125.	0.2	4
111	Morbidity after Total Gastrectomy: Analysis of 238 Patients. Journal of the American College of Surgeons, 2015, 220, 863-871e2.	0.2	65
112	Partial nephrectomy for renal tumors in solitary kidneys: postoperative renal function dynamics. World Journal of Urology, 2015, 33, 2023-2029.	1.2	12
113	Partial and Radical Nephrectomy for Unilateral Synchronous Multifocal Renal Cortical Tumors. Urology, 2015, 85, 1404-1410.	0.5	19
114	Unexpected Long-term Improvements in Urinary and Erectile Function in a Large Cohort of Men with Self-reported Outcomes Following Radical Prostatectomy. European Urology, 2015, 68, 899-905.	0.9	55
115	Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study. Journal of the National Cancer Institute, 2015, 107, .	3.0	146
116	Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case–Control Study. European Urology, 2015, 68, 207-213.	0.9	120
117	Minimally Invasive Partial Nephrectomy Versus Laparoscopic Cryoablation for Patients Newly Diagnosed with a Single Small Renal Mass. European Urology Focus, 2015, 1, 66-72.	1.6	11
118	Toward a Smarter Prostate Cancer Screening Program. European Urology, 2015, 68, 598-599.	0.9	1
119	Subcentimeter Pulmonary Nodules are Not Associated with Disease Progression in Patients with Renal Cell Carcinoma. Journal of Urology, 2015, 193, 776-782.	0.2	18
120	Urinary Cell mRNA Profiles and Differential Diagnosis of Acute Kidney Graft Dysfunction. Journal of the American Society of Nephrology: JASN, 2014, 25, 1586-1597.	3.0	45
121	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	0.9	195
122	Prostate Size and Adverse Pathologic Features in Men Undergoing Radical Prostatectomy. Urology, 2014, 84, 153-157.	0.5	28
123	Impact of a Common Clinical Pathway on Length of Hospital Stay in Patients Undergoing Open and Minimally Invasive Kidney Surgery. Journal of Urology, 2014, 191, 1225-1230.	0.2	32
124	Reply to Michael Froehner, Rainer Koch, and Manfred P. Wirth's Letter to the Editor re: Karim A. Touijer, Clarisse R. Mazzola, Daniel D. Sjoberg, Peter T. Scardino, James A. Eastham. Long-term Outcomes of Patients with Lymph Node Metastasis Treated with Radical Prostatectomy Without Adjuvant Androgen-deprivation Therapy. Eur Urol 2014;65:20–5. European Urology, 2014, 65, e25-e26.	0.9	0
125	Adult Prostate Sarcoma: The Memorial Sloan Kettering Experience. Urology, 2014, 84, 624-628.	0.5	38
126	Clinical Outcome of Patients with T1 Micropapillary Urothelial Carcinoma of the Bladder. Journal of Urology, 2014, 192, 702-707.	0.2	61

#	Article	IF	CITATIONS
127	Effect of Repeated Prostate Biopsies on Erectile Function in Men on Active Surveillance for Prostate Cancer. Journal of Urology, 2014, 191, 744-749.	0.2	47
128	Predictors of Cancer-specific Mortality After Disease Recurrence in Patients with Squamous Cell Carcinoma of the Penis. European Urology, 2014, 66, 811-814.	0.9	12